NO20061345L - Interfererende RNA-duplekser med butte ender og 3'-modifiseringer - Google Patents

Interfererende RNA-duplekser med butte ender og 3'-modifiseringer

Info

Publication number: NO20061345L
Authority: NO; Norway
Prior art keywords: aryl; alkyl; group; modifications; formula
Prior art date: 2003-08-28

Application number

NO20061345A

Other languages

English (en)

Norwegian (no)

Inventor

Jonathan Hall

Jean-Charles Bologna

Francois Jean-Charles Natt

Robert Haner

Jan Weiler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-28

Filing date

2006-03-24

Publication date

2006-05-29

2006-03-24 Application filed by Novartis Ag filed Critical Novartis Ag

2006-05-29 Publication of NO20061345L publication Critical patent/NO20061345L/no

Links

238000012986 modification Methods 0.000 title abstract 2
230000004048 modification Effects 0.000 title abstract 2
230000002452 interceptive effect Effects 0.000 title 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 4
125000000217 alkyl group Chemical group 0.000 abstract 4
125000003710 aryl alkyl group Chemical group 0.000 abstract 4
125000003118 aryl group Chemical group 0.000 abstract 4
125000005842 heteroatom Chemical group 0.000 abstract 4
108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 2
125000000524 functional group Chemical group 0.000 abstract 2
208000035657 Abasia Diseases 0.000 abstract 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
230000009368 gene silencing by RNA Effects 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
239000002342 ribonucleoside Substances 0.000 abstract 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Virology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20061345A 2003-08-28 2006-03-24 Interfererende RNA-duplekser med butte ender og 3'-modifiseringer NO20061345L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49851403P	2003-08-28	2003-08-28
PCT/EP2004/009599 WO2005021749A1 (fr)	2003-08-28	2004-08-27	Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'

Publications (1)

Publication Number	Publication Date
NO20061345L true NO20061345L (no)	2006-05-29

Family

ID=34272687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20061345A NO20061345L (no)	2003-08-28	2006-03-24	Interfererende RNA-duplekser med butte ender og 3'-modifiseringer

Country Status (21)

Country	Link
US (2)	US20070203084A1 (fr)
EP (3)	EP2338995A3 (fr)
JP (2)	JP2007503803A (fr)
KR (3)	KR101059315B1 (fr)
CN (2)	CN1845993B (fr)
AU (1)	AU2004269150C1 (fr)
BR (1)	BRPI0413146A (fr)
CA (1)	CA2536333C (fr)
CO (1)	CO5680494A2 (fr)
EC (1)	ECSP066388A (fr)
IL (1)	IL173565A (fr)
IS (1)	IS8358A (fr)
MA (1)	MA28029A1 (fr)
MX (1)	MXPA06002216A (fr)
NO (1)	NO20061345L (fr)
NZ (1)	NZ545360A (fr)
RU (2)	RU2399671C2 (fr)
SG (1)	SG152279A1 (fr)
TN (1)	TNSN06065A1 (fr)
WO (1)	WO2005021749A1 (fr)
ZA (1)	ZA200601003B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ545360A (en)	2003-08-28	2009-06-26	Novartis Ag	Interfering RNA duplex having blunt-ends and 3'-modifications
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
EP2076600A1 (fr) *	2006-10-18	2009-07-08	Nastech Pharmaceutical Company Inc.	Molécules d'acide nucléique ouvertes ou coupées et leurs utilisations
JP4900943B2 (ja) *	2006-12-25	2012-03-21	独立行政法人産業技術総合研究所	ヌクレアーゼ耐性及びｒｎａ干渉効果に優れた修飾型二本鎖ｒｎａ
JP5558346B2 (ja)	2007-07-05	2014-07-23	ノバルティスアーゲー	ウイルス感染を処置するためのｄｓＲＮＡ
US20110020368A1 (en)	2008-03-25	2011-01-27	Nancy Hynes	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
US20110311521A1 (en)	2009-03-06	2011-12-22	Pico Caroni	Novel therapy for anxiety
EP2241323A1 (fr)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascine-W et cancers du cerveau
EP2292266A1 (fr)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Traitement du cancer en modulant la copine III
US20120244170A1 (en)	2009-09-22	2012-09-27	Rafal Ciosk	Treating cancer by modulating mex-3
WO2011045352A2 (fr)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Tyrosine kinase de la rate et cancers du cerveau
WO2011072082A2 (fr) *	2009-12-09	2011-06-16	Nitto Denko Corporation	Modulation de l'expression de hsp47
CA2784783C (fr)	2009-12-18	2021-07-20	Novartis Ag	Compositions organiques de traitement des pathologies liees a hsf1
WO2011076807A2 (fr)	2009-12-23	2011-06-30	Novartis Ag	Lipides, compositions lipidiques, et procédés d'utilisation associés
BR112012019902A2 (pt)	2010-02-10	2019-09-24	Novartis Ag	"método e compostos para o crescimento muscular"
WO2011107586A1 (fr)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, ténascine-c et cancers du cerveau
US20130034543A1 (en)	2010-04-19	2013-02-07	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Modulating xrn1
US10913767B2 (en) *	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
CA2797051C (fr)	2010-04-23	2021-01-12	Novartis Ag	Compositions organiques pour traiter des maladies associees a beta-enac
EP2580239A1 (fr)	2010-06-10	2013-04-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Traitement du cancer par modulation de la kinase 3 stérile de mammifère de type 20
WO2012168259A1 (fr)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protéine tyrosine phosphatase de type non-récepteur 11 (ptpn11), et cancer du sein triple négatif
BR112014001398A2 (pt) *	2011-07-18	2020-12-01	Devgen Nv	regulação negativa da expressão genética em pragas de insetos
EP3521432A1 (fr)	2011-09-02	2019-08-07	Arrowhead Pharmaceuticals, Inc.	Compositions organiques de traitement de maladies associées à hsf1
WO2013068431A1 (fr)	2011-11-08	2013-05-16	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Traitement inédit contre les maladies neurodégénératives
WO2013068432A1 (fr)	2011-11-08	2013-05-16	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Diagnostic précoce de maladies neurodégénératives
AU2012338869A1 (en)	2011-11-15	2014-06-05	Novartis Ag	Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2-Signal Transducer and Activator of Transcription 5 pathway
EP2800583A1 (fr)	2012-01-02	2014-11-12	Novartis AG	Cdcp1 et cancer du sein
CA2860676A1 (fr)	2012-01-09	2013-07-18	Novartis Ag	Compositions organiques pour traiter des maladies associees a la beta-catenine
WO2013144240A1 (fr)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition de l'interleukine 8 et/ou de ses récepteurs cxcrl dans le traitement du cancer du sein surexprimant her2/her3
EP3272868A1 (fr)	2012-05-02	2018-01-24	Arrowhead Pharmaceuticals, Inc.	Compositions organiques pour traiter des maladies associées à kras
US10125362B2 (en) *	2012-05-22	2018-11-13	Olix Pharmaceuticals, Inc.	RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US20150218238A1 (en)	2012-06-29	2015-08-06	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en)	2012-07-05	2015-07-02	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	New treatment for neurodegenerative diseases
US20150224190A1 (en)	2012-07-06	2015-08-13	Mohamed Bentires-Alj	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
SG10201706960TA (en)	2013-02-28	2017-10-30	Arrowhead Res Corp	Organic compositions to treat epas1-related diseases
KR102144777B1 (ko) *	2013-06-19	2020-08-18	제이더블유중외제약 주식회사	결정형 메로페넴 삼수화물의 제조방법
EP3030902B1 (fr)	2013-08-07	2019-09-25	Friedrich Miescher Institute for Biomedical Research	Nouveau procédé de criblage pour traiter l'ataxie de friedreich
EP3052464B1 (fr)	2013-10-04	2020-04-15	Novartis AG	3'end caps pour des agents arni utilisés dans l'interférence d'arn
WO2015051044A2 (fr)	2013-10-04	2015-04-09	Novartis Ag	Formats inédits pour composés organiques utiisables en interférence arn
WO2015051135A2 (fr)	2013-10-04	2015-04-09	Novartis Ag	Compositions organiques destinées au traitement de maladies associées à l'hepcidine
CN105792832B (zh)	2013-10-04	2021-03-23	诺华股份有限公司	用于治疗乙肝病毒的有机化合物
WO2015051366A2 (fr)	2013-10-04	2015-04-09	Novartis Ag	Formats inédits pour composés organiques utilisables en interférence arn
KR101696704B1 (ko) *	2013-12-17	2017-01-16	주식회사 인코드젠	오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도
EP3154579A1 (fr)	2014-06-13	2017-04-19	Friedrich Miescher Institute for Biomedical Research	Nouveau traitement dirigé contre le virus de la grippe
EP3164129A1 (fr)	2014-07-01	2017-05-10	Friedrich Miescher Institute for Biomedical Research	Combinaison d'un inhibiteur de braf v600e et d'un inhibiteur de mertk pour le traitement du mélanome
WO2016010840A1 (fr)	2014-07-16	2016-01-21	Novartis Ag	Procédé d'encapsulation d'un acide nucléique dans une nanoparticule lipidique hôte
WO2016011123A1 (fr)	2014-07-16	2016-01-21	Arrowhead Research Corporation	Compositions organiques pour letraitement de pathologies liées à l'apoc3
US20180010132A1 (en)	2014-09-11	2018-01-11	Novartis Ag	Inhibition of prmt5 to treat mtap-deficiency-related diseases
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
WO2016089883A1 (fr)	2014-12-01	2016-06-09	Novartis Ag	Compositions et méthodes pour le diagnostic et le traitement du cancer de la prostate
EP3302525A2 (fr)	2015-06-05	2018-04-11	Novartis AG	Méthodes et compositions permettant de diagnostiquer, traiter et surveiller le traitement de troubles associés à une déficience en shank3
US20180348224A1 (en)	2015-10-28	2018-12-06	Friedrich Miescher Institute For Biomedical Resear Ch	Tenascin-w and biliary tract cancers
JOP20200228A1 (ar)	2015-12-21	2017-06-16	Novartis Ag	تركيبات وطرق لخفض تعبير البروتين tau
US9721645B1 (en)	2016-01-29	2017-08-01	Taiwan Semiconductor Manufacturing Company, Ltd.	SRAM arrays and methods of manufacturing same
WO2018047148A1 (fr)	2016-09-12	2018-03-15	Novartis Ag	Composés pour inhibition du miarn
WO2018083606A1 (fr)	2016-11-01	2018-05-11	Novartis Ag	Procédés et compositions pour améliorer l'édition de gènes
WO2019016772A2 (fr)	2017-07-21	2019-01-24	Novartis Ag	Compositions et procédés permettant de traiter un cancer
JOP20200054A1 (ar)	2017-09-11	2020-03-10	Arrowhead Pharmaceuticals Inc	عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
US20210123016A1 (en)	2018-05-02	2021-04-29	Novartis Ag	Regulators of human pluripotent stem cells and uses thereof
CA3120580A1 (fr)	2019-01-09	2020-07-16	Arrowhead Pharmaceuticals, Inc.	Agents d'arni pour inhiber l'expression de hif-2 alpha (epas1), leurs compositions et methodes d'utilisation
TW202440941A (zh)	2022-12-20	2024-10-16	瑞士商諾華公司	核酸連接方法
AR131405A1 (es)	2022-12-20	2025-03-19	Novartis Ag	Ligasas modificadas y usos de las mismas
WO2025262452A1 (fr)	2024-06-18	2025-12-26	Novartis Ag	Procédé de ligature d'acide nucléique

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0497875B1 (fr)	1989-10-24	2000-03-22	Isis Pharmaceuticals, Inc.	Oligonucleotides modifies en position 2'
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US6005087A (en)	1995-06-06	1999-12-21	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US6033909A (en)	1992-01-22	2000-03-07	Hoechst Aktiengesellschaft	Oligonucleotide analogs, their preparation and use
NZ245720A (en)	1992-01-22	1995-12-21	Hoechst Ag	Oligonucleotide analogues; use as gene expression inhibitor or dna probe
ATE285477T1 (de)	1995-06-07	2005-01-15	Inex Pharmaceutical Corp	Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5981501A (en)	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
WO2002096927A2 (fr) *	2001-05-29	2002-12-05	Ribozyme Pharmaceuticals, Incorporated	Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme
US5998203A (en) *	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
WO1998051278A2 (fr)	1997-05-14	1998-11-19	Inex Pharmaceuticals Corporation	Encapsulation hautement efficace d'agents therapeutiques charges dans des vesicules lipidiques
RU2217161C2 (ru) *	1997-08-26	2003-11-27	Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.)	Способ лечения вирусного гепатита
US6506559B1 (en)	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
US6211349B1 (en)	1998-12-30	2001-04-03	Oligos Etc., Inc.	Protonated/acidified nucleic acids and methods of use
EP2314700A1 (fr)	1999-01-28	2011-04-27	Medical College of Georgia Research Institute, Inc	Composition et méthode destinées à l'attenuation in vivo et in vitro de l'expression génique utilisant de l'ARN double brin
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en)	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
DE10160151A1 (de)	2001-01-09	2003-06-26	Ribopharma Ag	Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050233329A1 (en)	2002-02-20	2005-10-20	Sirna Therapeutics, Inc.	Inhibition of gene expression using duplex forming oligonucleotides
WO2003070918A2 (fr) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
US20070026394A1 (en)	2000-02-11	2007-02-01	Lawrence Blatt	Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
PT1309726E (pt)	2000-03-30	2010-03-08	Whitehead Biomedical Inst	Mediadores de interferência por rna específicos de sequência de rna
US20030190635A1 (en)	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
KR100909681B1 (ko)	2000-12-01	2009-07-29	막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우.	Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20020132257A1 (en)	2001-01-31	2002-09-19	Tony Giordano	Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20070032441A1 (en)	2001-05-18	2007-02-08	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20030175950A1 (en)	2001-05-29	2003-09-18	Mcswiggen James A.	RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040019001A1 (en)	2002-02-20	2004-01-29	Mcswiggen James A.	RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
AU2004266311B2 (en)	2001-05-18	2009-07-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20090247606A1 (en)	2001-08-28	2009-10-01	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
US8258288B2 (en)	2002-02-20	2012-09-04	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
BRPI0313202A8 (pt) *	2002-08-05	2016-08-16	Atugen Ag	Formas adicionais para interferir com as moléculas de rna
DK1389637T3 (da) *	2002-08-05	2012-09-03	Silence Therapeutics Ag	Interfererende RNA-molekyler med stumpe ender
WO2004090105A2 (fr) *	2003-04-02	2004-10-21	Dharmacon, Inc.	Polynucleotides modifies utilisables pour l'interference arn
US20070270360A1 (en) *	2003-04-15	2007-11-22	Sirna Therapeutics, Inc.	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
EP2669377A3 (fr)	2003-04-17	2015-10-14	Alnylam Pharmaceuticals Inc.	Agents iARN modifiés
EP1636385A4 (fr)	2003-06-24	2010-06-02	Mirus Bio Corp	Inhibition d'une fonction genique par distribution in vivo d'inhibiteurs d'expression genique a base de polynucleotides dans des cellules mammiferes
NZ545360A (en)	2003-08-28	2009-06-26	Novartis Ag	Interfering RNA duplex having blunt-ends and 3'-modifications
AU2005247509C1 (en)	2004-05-27	2012-09-20	Alnylam Pharmaceuticals, Inc.	Nuclease resistant double-stranded ribonucleic acid
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds

2004
- 2004-08-27 NZ NZ545360A patent/NZ545360A/en not_active IP Right Cessation
- 2004-08-27 WO PCT/EP2004/009599 patent/WO2005021749A1/fr not_active Ceased
- 2004-08-27 MX MXPA06002216A patent/MXPA06002216A/es active IP Right Grant
- 2004-08-27 KR KR1020087007645A patent/KR101059315B1/ko not_active Expired - Fee Related
- 2004-08-27 JP JP2006524342A patent/JP2007503803A/ja active Pending
- 2004-08-27 CN CN2004800249803A patent/CN1845993B/zh not_active Expired - Lifetime
- 2004-08-27 AU AU2004269150A patent/AU2004269150C1/en not_active Expired
- 2004-08-27 KR KR1020117000474A patent/KR20110007263A/ko not_active Ceased
- 2004-08-27 BR BRPI0413146-0A patent/BRPI0413146A/pt not_active IP Right Cessation
- 2004-08-27 EP EP10184568A patent/EP2338995A3/fr not_active Withdrawn
- 2004-08-27 CA CA2536333A patent/CA2536333C/fr not_active Expired - Lifetime
- 2004-08-27 SG SG200902906-7A patent/SG152279A1/en unknown
- 2004-08-27 KR KR1020067004048A patent/KR20060087531A/ko not_active Ceased
- 2004-08-27 EP EP12151831A patent/EP2489737A1/fr not_active Withdrawn
- 2004-08-27 US US10/569,927 patent/US20070203084A1/en not_active Abandoned
- 2004-08-27 RU RU2006109547/13A patent/RU2399671C2/ru not_active IP Right Cessation
- 2004-08-27 CN CN2010101678324A patent/CN101914533B/zh not_active Expired - Fee Related
- 2004-08-27 EP EP04764573A patent/EP1660657A1/fr not_active Ceased
2006
- 2006-02-03 ZA ZA200601003A patent/ZA200601003B/en unknown
- 2006-02-06 IL IL173565A patent/IL173565A/en active IP Right Grant
- 2006-02-22 EC EC2006006388A patent/ECSP066388A/es unknown
- 2006-02-27 TN TNP2006000065A patent/TNSN06065A1/en unknown
- 2006-03-08 MA MA28861A patent/MA28029A1/fr unknown
- 2006-03-17 IS IS8358A patent/IS8358A/is unknown
- 2006-03-21 CO CO06027688A patent/CO5680494A2/es not_active Application Discontinuation
- 2006-03-24 NO NO20061345A patent/NO20061345L/no not_active Application Discontinuation
2008
- 2008-12-18 US US12/338,601 patent/US8097716B2/en not_active Expired - Lifetime
2010
- 2010-05-14 RU RU2010119292/10A patent/RU2010119292A/ru not_active Application Discontinuation
- 2010-08-26 JP JP2010189117A patent/JP2011160796A/ja active Pending

Also Published As

Publication number	Publication date
US20070203084A1 (en)	2007-08-30
MA28029A1 (fr)	2006-07-03
US20090192113A1 (en)	2009-07-30
CN101914533A (zh)	2010-12-15
TNSN06065A1 (en)	2007-10-03
AU2004269150B2 (en)	2009-06-04
US8097716B2 (en)	2012-01-17
CN101914533B (zh)	2013-06-19
MXPA06002216A (es)	2006-04-27
JP2007503803A (ja)	2007-03-01
RU2399671C2 (ru)	2010-09-20
RU2010119292A (ru)	2011-12-10
EP2338995A3 (fr)	2012-01-11
EP1660657A1 (fr)	2006-05-31
WO2005021749A1 (fr)	2005-03-10
EP2489737A1 (fr)	2012-08-22
CO5680494A2 (es)	2006-09-29
AU2004269150C1 (en)	2010-11-18
IL173565A0 (en)	2006-07-05
JP2011160796A (ja)	2011-08-25
KR101059315B1 (ko)	2011-08-24
KR20110007263A (ko)	2011-01-21
ECSP066388A (es)	2006-08-30
ZA200601003B (en)	2007-04-25
KR20060087531A (ko)	2006-08-02
IL173565A (en)	2012-07-31
RU2006109547A (ru)	2007-10-10
KR20080034046A (ko)	2008-04-17
IS8358A (is)	2006-03-17
EP2338995A2 (fr)	2011-06-29
CA2536333C (fr)	2013-01-08
CN1845993B (zh)	2010-06-23
BRPI0413146A (pt)	2006-10-03
CN1845993A (zh)	2006-10-11
SG152279A1 (en)	2009-05-29
AU2004269150A1 (en)	2005-03-10
CA2536333A1 (fr)	2005-03-10
NZ545360A (en)	2009-06-26

Legal Events

Date	Code	Title	Description
2013-03-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20061345L (no)	2006-05-29	Interfererende RNA-duplekser med butte ender og 3'-modifiseringer
ATE287897T2 (de)	2005-02-15	Analoga von nukleosiden und oligonukleotiden
CA2565660A1 (fr)	2005-11-10	Composes aryl- ou heteroarylamides ortho-substitues
WO2005105732A8 (fr)	2007-04-19	Composes methylaryl- ou heteroarylamides substitues
RU2436785C2 (ru)	2011-12-20	Гетеробициклические карбоксамиды в качестве ингибиторов киназ
KR900004729A (ko)	1990-04-12	페닐기를 갖는 아미드를 기재로한 항진균제
JP7138349B2 (ja)	2022-09-16	核酸化合物およびオリゴヌクレオチド
EP2354148A3 (fr)	2011-10-19	Analogues de nucléoside et dérive d'oligonucléotides comportant un analogue de nucléotide
WO2009127948A8 (fr)	2010-09-23	Composés aryl carboxamides à 5 éléments de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
BR0311338A (pt)	2005-03-22	Derivados de n-acilaminobenzeno como inibidores seletivos da monoamina oxidade b
EP1106607A3 (fr)	2001-07-18	Composés d'uracile et leur usage
PE20020524A1 (es)	2002-06-18	7-oxo-piridopirimidinas como inhibidores de quinasas
WO2009127949A8 (fr)	2010-09-30	Composés aryl carboxamides de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
MA27078A1 (fr)	2004-12-20	Derives de 2-amino-thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
EP1225174A4 (fr)	2002-10-23	Cristaux de mirtazapine anhydres et leur procede de fabrication
ATE376553T1 (de)	2007-11-15	Heterozyklisch-substituierte (thio)phosphorsäuretriamide
EP1036793A3 (fr)	2001-02-28	Procédé pour la préparation des dérivés de 2-alkyle-3-aminothiophene et 3-aminothiophene
WO2003061652A8 (fr)	2004-09-10	Acides 3-(imidazolyl)-2-alkoxypropanoiques servant d'inhibiteurs tafia
EP0816353B1 (fr)	2001-12-19	Dérivés de coumarine, procédés pour leur préparation et leur usage
PT968189E (pt)	2002-04-29	Processo para a preparacao de acidos nicotinicos
NO20061424L (no)	2006-03-29	Fremgangsmote for fremstillingen av THIP
EP1127873A3 (fr)	2003-05-07	Procédé pour la préparation de benzoylcyanide amidinohydrazones
Elliott et al.	1981	Nucleosides containing chemically reactive groups
TW200612912A (en)	2006-05-01	Benzyloxy derivatives as maob inhibitors
Todorović et al.	2006	DNA triplex stabilization by a δ-carboline derivative tethered to third strand oligonucleotides